Abstract
Background
Ablation for atrial flutter and continued pharmacologic therapy (hybrid therapy) is a management strategy when treatment with class I antiarrhythmic drugs organize atrial fibrillation (AF) into flutter. Previous studies with 2–3-year follow-up have reported satisfactory control of AF burden.
Objective
We evaluated the effectiveness of hybrid therapy after a follow-up of 5 years. We hypothesized that longer term follow-up would demonstrate eventual failure of this strategy to control AF.
Methods
A consecutive, retrospective evaluation of all first time ablations of right atrial flutter at the University of Pennsylvania between August 2003 and August 2005 was performed (n = 179). The study population consisted of 33 patients who had atrial flutter only after treatment of AF with class I antiarrhythmic drugs and was continued on them post-ablation. Follow-up data were obtained by reviewing records from our institution, from referring cardiologists, and from direct patient questionnaires.
Results
Atrial fibrillation recurrence was noted in 28 of 31 patients (90.3 %) who completed 5 years of follow-up. AF recurrence typically resulted in significant symptoms, although 21 % developed persistent AF and were eventually minimally symptomatic on a rate control strategy. A wide range of time to recurrence was observed (0.2–64.5 months) with 39 % recurring greater than 2 years post-ablation.
Conclusion
Hybrid therapy is not effective for long-term control of AF. Patients should be counseled about the likelihood of eventual AF recurrence and anticoagulation should be maintained indefinitely when this strategy is used.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Garrey, W. E. (1924). Auricular fibrillation. Physiological Reviews, 4, 215–250.
Nabar, A., Rodriguez, L. M., Timmermans, C., van Mechelen, R., & Wellens, H. J. (2001). Class ic antiarrhythmic drug induced atrial flutter: Electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. Heart, 85, 424–429.
Gerstenfeld, E. P., Sahakian, A. V., & Swiryn, S. (1992). Evidence for transient linking of atrial excitation during atrial fibrillation in humans. Circulation, 86, 375–382.
Page, P. L., Plumb, V. J., Okumura, K., & Waldo, A. L. (1986). A new animal model of atrial flutter. Journal of the American College of Cardiology, 8, 872–879.
Shimizu, A., Nozaki, A., Rudy, Y., & Waldo, A. L. (1991). Onset of induced atrial flutter in the canine pericarditis model. Journal of the American College of Cardiology, 17, 1223–1234.
Movsowitz, C. C. D., Schwartzman, D., Gottlieb, C., & Marchlinski, F. E. (1996). The results of atrial flutter ablation in patients with and without a history of atrial fibrillation. The American Journal of Cardiology, 78, 93–96.
Huang, D. T., Monahan, K. M., Zimetbaum, P., Papageorgiou, P., Epstein, L. M., & Josephson, M. E. (1998). Hybrid pharmacologic and ablative therapy: A novel and effective approach for the management of atrial fibrillation. Journal of Cardiovascular Electrophysiology, 9, 462–469.
Stabile, G., De Simone, A., Turco, P., La Rocca, V., Nocerino, P., Astarita, C., et al. (2001). Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. Journal of the American College of Cardiology, 37, 1639–1644.
Reithmann, C., Dorwarth, U., Dugas, M., Hahnefeld, A., Ramamurthy, S., Remp, T., et al. (2003). Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug-induced atrial flutter. European Heart Journal, 24, 1264–1272.
Turco, P., De Simone, A., La Rocca, V., El Jamal, B., Nocerino, P., Astarita, C., et al. (2005). Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion. Pacing and Clinical Electrophysiology, 28(Suppl 1), S124–S127.
Chinitz, J. S. (2007). GE, Marchlinski FE, Callans DJ. Atrial fibrillation is common after ablation of isolated atrial flutter during long-term follow –up. Heart Rhythm, 4, 1029–1033.
Coyne RF, D. M., Gottlieb, C. D., Marchlinski, F. E., & Callans, D. J. (2000). Electroanatomic magnetic mapping during ablation of isthmus-dependent atrial flutter. Journal Interventional Cardiovascular Electrophysiology, 4, 635–643.
Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., et al. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, 114, e257–e354.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Anastasio, N., Frankel, D.S., Deyell, M.W. et al. Nearly uniform failure of atrial flutter ablation and continuation of antiarrhythmic agents (hybrid therapy) for the long-term control of atrial fibrillation. J Interv Card Electrophysiol 35, 57–61 (2012). https://doi.org/10.1007/s10840-012-9679-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10840-012-9679-0